ArriVent BioPharma, Inc.
AVBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868279
No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q3 2025
Institutional positions in ArriVent BioPharma, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- +7 vs. Q2 2025
- Shares held
- 38.6M
- +4.94M (+14.7%) vs. Q2 2025
- Total value
- $712.4M
- −$19.7M (−2.7%) vs. Q2 2025
- New holders
- 18
- 46 more added
- Sold out
- 11
- 19 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AVBP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 157 | $1.60B |
| Q1 2026 | 139 | $969.5M |
| Q4 2025 | 122 | $810.3M |
| Q3 2025 | 106 | $712.4M |
| Q2 2025 | 99 | $732.0M |
| Q1 2025 | 83 | $539.3M |
| Q4 2024 | 80 | $757.5M |
| Q3 2024 | 68 | $612.3M |
| Q2 2024 | 54 | $404.2M |
| Q1 2024 | 53 | $388.9M |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding ArriVent BioPharma, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,046,138 | $37.8M | 0.00% | +207,762+11.3% | Added |
| OrbiMed Advisors LLC | 3,027,328 | $55.9M | 1.34% | 00.0% | Unchanged |
| FMR LLC | 3,407,549 | $62.9M | 0.00% | +1,349,480+65.6% | Added |
| Suvretta Capital Management, LLC | 3,703,452 | $68.3M | 2.07% | +290,664+8.5% | Added |
| Infinitum Asset Management, LLC | 3,868,923 | $71.4M | 13.13% | +450,000+13.2% | Added |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 4,484,672 | $82.7M | 2.02% | 00.0% | Unchanged |
| Weiss Asset Management LP | 0 | $0 | 0.00% | −53,786−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −33,655−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −29,611−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −25,346−100.0% | Sold out |
| Susquehanna Portfolio Strategies, LLC | 0 | $0 | 0.00% | −20,056−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −14,292−100.0% | Sold out |
| Intech Investment Management LLC | 0 | $0 | 0.00% | −13,461−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −12,735−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −12,530−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −9,592−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −8,730−100.0% | Sold out |